A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas
A phase 3 trial of Belantamab mafodotin, Lenalidomide, Dexamethasone in multiple myeloma, run by GlaxoSmithKline, now recruiting.
Overview
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) is a phase 3 interventional study registered as NCT06679101 by GlaxoSmithKline, with 520 participants planned, started 2024-12-16 and due to reach its primary completion in 2031-04-28. Interventions recorded: Belantamab mafodotin, Lenalidomide, Dexamethasone, Daratumumab. Conditions listed: Multiple Myeloma, Newly Diagnosed Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialChina Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame
Shares Belantamab mafodotin, Daratumumab, GSK, Dexamethasone.
- TrialJapan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex
Shares Belantamab mafodotin, Daratumumab, GSK, Dexamethasone.
- TrialSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
Shares Belantamab mafodotin, GSK, Dexamethasone, Lenalidomide.
- TrialA Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme
Shares Belantamab mafodotin, GSK, Dexamethasone, Multiple myeloma.
- TrialA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena
Shares Daratumumab, Dexamethasone, Lenalidomide, Multiple myeloma.
- TrialStudy of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple
Shares Belantamab mafodotin, GSK, Multiple myeloma.
- TrialAll Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo
Shares Belantamab mafodotin, GSK, Dexamethasone, Multiple myeloma.
- TrialSub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi
Shares Belantamab mafodotin, GSK, Dexamethasone, Multiple myeloma.